STOCK PURCHASE AGREEMENT BY AND BETWEEN REGENERON PHARMACEUTICALS, INC. AND INTELLIA THERAPEUTICS, INC. DATED AS OF MAY 30, 2020Stock Purchase Agreement • June 1st, 2020 • Intellia Therapeutics, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of May 30, 2020, by and between Regeneron Pharmaceuticals, Inc. (the “Investor”), a New York corporation with its principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591, and Intellia Therapeutics, Inc. (the “Company”), a Delaware corporation with its principal place of business at 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139.
AMENDMENT 1 TO LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • June 1st, 2020 • Intellia Therapeutics, Inc. • In vitro & in vivo diagnostic substances • New York
This Amendment 1 (this “Amendment”), dated as of May 30, 2020 (the “Amendment Date”), is entered into by and between REGENERON PHARMACEUTICALS, INC., a corporation organized under the laws of New York and having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (“Regeneron”), and INTELLIA THERAPEUTICS, INC., a corporation organized under the laws of Delaware and having a principal place of business at 40 Erie Street, Suite 130, Cambridge, MA 02139 (“Intellia”) (with each of Regeneron and Intellia referred to herein individually as a “Party” and collectively as the “Parties”).
